Trial paused: can a liver drug stop Cancer-Causing polyps?
NCT ID NCT05223036
Summary
This study is testing whether a drug called obeticholic acid (OCA), already approved for a liver disease, can safely reduce the number of intestinal polyps in people with familial adenomatous polyposis (FAP). FAP is a genetic condition that causes many polyps to grow in the gut, which can turn into cancer. About 80 adult participants will take either the drug or a placebo pill daily for six months to see if OCA lowers their polyp burden.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259, United States
-
University of Kansas Cancer Center
Kansas City, Kansas, 66160, United States
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
-
University of Puerto Rico
San Juan, 00936, Puerto Rico
Conditions
Explore the condition pages connected to this study.